Trial
NCT01423539
A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Genentech, Inc.
Collaborators
AbbVie (prior sponsor, Abbott)
Condition
Diffuse Large B-Cell Lymphoma
Intervention
bendamustine
Why stopped
The NAVIGATE study has been terminated due to non-safety related reasons.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-11-02